Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of TTR amyloidosis~* Adequate blood counts, liver and renal function~* Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must use an adequate method of birth control~* Males agree to use appropriate contraception~* Willing and able to comply with protocol-required visit schedule and visit requirements and provide written informed consent.~Exclusion Criteria:~* Known human immunodeficiency virus (HIV) positive status~* Receiving antibiotics for bacterial infection within 7 days of screening~* Known or suspected systemic viral, parasitic or fungal infection~* Receiving an investigational agent within 30 days prior to study drug administration~* Poor cardiac function~* Considered unfit for the study by the Principal Investigator~* Known sensitivity to oligonucleotides~* Employee or family member of the sponsor or the clinical study site personnel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALN-TTR01 (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).